Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

按照协议，礼来公司将启动一项“真实世界”研究，旨在了解替西帕肽（tirzepatide，其Zepbound和Mounjaro药物背后的GLP-1受体激动剂药物）如何影响减肥、糖尿病预防和肥胖相关并发症的预防，以更好地为英国国家卫生服务局（NHS）应对 ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...